Ivermectin administration is associated with lower gastrointestinal complications and greater ventilator-free days in ventilated patients with COVID-19: A propensity score analysis
Shimizu et al.,
Ivermectin administration is associated with lower gastrointestinal complications and greater ventilator-free..,
Journal of Infection and Chemotherapy, doi:10.1016/j.jiac.2021.12.024
Retrospective 88 ventilated COVID-19 patients in Japan, 39 treated with ivermectin within 3 days of admission, showing significantly reduced incidence of GI complications and mortality, and increased ventilator-free days with treatment.
risk of death, 99.9% lower, HR 0.001, p < 0.001, treatment 0 of 39 (0.0%), control 8 of 49 (16.3%), NNT 6.1, adjusted per study, Cox proportional hazard regression.
|
ventilator free days, 47.9% lower, OR 0.52, p = 0.03, treatment 39, control 49, adjusted per study, inverted to make OR<1 favor treatment, proportional odds logistic regression, primary outcome, RR approximated with OR.
|
ventilation time, 38.5% lower, relative time 0.62, p < 0.001, treatment 39, control 49.
|
ICU free days, 42.8% lower, OR 0.57, p = 0.06, treatment 39, control 49, adjusted per study, inverted to make OR<1 favor treatment, proportional odds logistic regression, RR approximated with OR.
|
ICU time, 37.5% lower, relative time 0.62, p < 0.001, treatment 39, control 49.
|
GI complications while ventilated, 77.9% lower, RR 0.22, p = 0.03, treatment 39, control 49, adjusted per study, Cox proportional hazard regression.
|
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
|

Shimizu et al., 31 Dec 2021, retrospective, Japan, peer-reviewed, 11 authors, study period December 2020 - May 2021, dosage 200μg/kg days 1, 14.
Abstract: Journal Pre-proof
Ivermectin administration is associated with lower gastrointestinal complications and
greater ventilator-free days in ventilated patients with COVID-19: A propensity score
analysis
Kentaro Shimizu, Haruhiko Hirata, Daijiro Kabata, Natsuko Tokuhira, Moe Koide,
Akiko Ueda, Jotaro Tachino, Ayumi Shintani, Akinori Uchiyama, Yuji Fujino, Hiroshi
Ogura
PII:
S1341-321X(21)00360-3
DOI:
https://doi.org/10.1016/j.jiac.2021.12.024
Reference:
JIC 1790
To appear in:
Journal of Infection and Chemotherapy
Received Date: 18 September 2021
Revised Date:
11 November 2021
Accepted Date: 26 December 2021
Please cite this article as: Shimizu K, Hirata H, Kabata D, Tokuhira N, Koide M, Ueda A, Tachino
J, Shintani A, Uchiyama A, Fujino Y, Ogura H, Ivermectin administration is associated with lower
gastrointestinal complications and greater ventilator-free days in ventilated patients with COVID-19: A
propensity score analysis, Journal of Infection and Chemotherapy (2022), doi: https://doi.org/10.1016/
j.jiac.2021.12.024.
This is a PDF file of an article that has undergone enhancements after acceptance, such as the addition
of a cover page and metadata, and formatting for readability, but it is not yet the definitive version of
record. This version will undergo additional copyediting, typesetting and review before it is published
in its final form, but we are providing this version to give early visibility of the article. Please note that,
during the production process, errors may be discovered which could affect the content, and all legal
disclaimers that apply to the journal pertain.
© 2021 Japanese Society of Chemotherapy and The Japanese Association for Infectious Diseases.
Published by Elsevier Ltd. All rights reserved.
(Title Page)
1) Title
Ivermectin administration is associated with lower gastrointestinal complications and greater
ventilator-free days in ventilated patients with COVID-19: A propensity score analysis
oo
f
2) Author names and affiliations
re
-p
r
(Authors)
Kentaro Shimizu1, shimiken@hp-emerg.med.osaka-u.ac.jp
lP
Haruhiko Hirata2, charhirata@imed3.med.osaka-u.ac.jp
ur
na
Daijiro Kabata3, kabata.daijiro@med.osaka-cu.ac.jp
Natsuko Tokuhira4, tokuhira@hosp.med.osaka-u.ac.jp
Jo
Moe Koide4, koide@hosp.med.osaka-u.ac.jp
Akiko Ueda5, aueda@hp-lab.med.osaka-u.ac.jp
Jotaro Tachino1, jotarotachino@hp-emerg.med.osaka-u.ac.jp
Ayumi Shintani, ayumi.shintani@gmail.com
Akinori Uchiyama4, auchiyama@hp-icu.med.osaka-u.ac.jp
Yuji Fujino4, fujino@anes.med.osaka-u.ac.jp
Hiroshi Ogura1, ogura@hp-emerg.med.osaka-u.ac.jp
(Affiliations)
1
1
Department of Traumatology and Acute Critical Medicine, Osaka University Graduate School of
Medicine, Suita, Osaka, Japan
2
Department of Respiratory Medicine and Clinical Immunology, Graduate School of Medicine, Osaka
University
2-2 Yamadaoka, Suita 565-0871, Japan
3
oo
f
Department of Medical Statistics, Osaka City University Graduate School of Medicine, 1-4-3,
4
re
-p
r
Asahimachi, Abeno-ku, Osaka, 545-0051, Japan
Intensive Care Unit, Osaka University Hospital, Osaka University, Japan
lP
2-15 Yamadaoka, Suita, Osaka 565-0871, Japan
5
ur
na
Laboratory for Clinical Investigation, Osaka University Hospital, Osaka University, Japan
Jo
2-15 Yamadaoka, Suita, Osaka 565-0871, Japan
3) Corresponding author:
Kentaro Shimizu, M.D.
Department of Traumatology and Acute Critical Medicine, Osaka University Graduate School of
Medicine, 2-15 Yamadaoka, Suita-city, Osaka..
Late treatment
is less effective
Please send us corrections, updates, or comments. Vaccines and
treatments are complementary. All practical, effective, and safe means should
be used based on risk/benefit analysis. No treatment, vaccine, or intervention
is 100% available and effective for all current and future variants. We do not
provide medical advice. Before taking any medication, consult a qualified
physician who can provide personalized advice and details of risks and
benefits based on your medical history and situation.
FLCCC and
WCH
provide treatment protocols.
Submit